About Apogee Therapeutics, Inc.
https://www.apogeetherapeutics.comApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
CEO
Michael Thomas Henderson
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 125
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VR ADVISER, LLC
Shares:8.49M
Value:$700.1M
FMR LLC
Shares:6.92M
Value:$570.12M
WELLINGTON MANAGEMENT GROUP LLP
Shares:4.72M
Value:$389.37M
Summary
Showing Top 3 of 185
About Apogee Therapeutics, Inc.
https://www.apogeetherapeutics.comApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $70.88M ▼ | $-65.02M ▲ | 0% | $-1.11 ▲ | $-64.56M ▲ |
| Q2-2025 | $0 | $73.17M ▲ | $-66.1M ▼ | 0% | $-1.13 ▼ | $-72.77M ▼ |
| Q1-2025 | $0 | $63.1M ▼ | $-55.34M ▲ | 0% | $-0.95 ▲ | $-62.89M ▲ |
| Q4-2024 | $0 | $75.88M ▲ | $-67.22M ▼ | 0% | $-1.22 ▼ | $-75.81M ▼ |
| Q3-2024 | $0 | $58.69M | $-49.02M | 0% | $-0.86 | $-58.64M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $527.29M ▲ | $626.16M ▼ | $39.82M ▲ | $586.34M ▼ |
| Q2-2025 | $505.42M ▼ | $657.77M ▼ | $38.37M ▼ | $619.4M ▼ |
| Q1-2025 | $513.33M ▼ | $714.16M ▼ | $40.8M ▲ | $673.36M ▼ |
| Q4-2024 | $520.65M ▼ | $753.95M ▼ | $37.16M ▼ | $716.79M ▼ |
| Q3-2024 | $526.05M | $776.29M | $41.88M | $734.4M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-65.02M ▲ | $-54.26M ▲ | $17.95M ▼ | $19.74M ▲ | $-16.57M ▼ | $-54.26M ▲ |
| Q2-2025 | $-66.1M ▼ | $-62.03M ▼ | $78.13M ▲ | $1.18M ▲ | $17.28M ▲ | $-62.8M ▼ |
| Q1-2025 | $-55.34M ▲ | $-48.48M ▲ | $12.98M ▼ | $622K ▼ | $-34.87M ▼ | $-52.79M ▲ |
| Q4-2024 | $-67.22M ▼ | $-67.71M ▼ | $46.37M ▲ | $44.36M ▲ | $23.01M ▲ | $-67.71M ▼ |
| Q3-2024 | $-49.02M | $-42.52M | $-146.38M | $383K | $-188.52M | $-43.27M |
CEO
Michael Thomas Henderson
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 125
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VR ADVISER, LLC
Shares:8.49M
Value:$700.1M
FMR LLC
Shares:6.92M
Value:$570.12M
WELLINGTON MANAGEMENT GROUP LLP
Shares:4.72M
Value:$389.37M
Summary
Showing Top 3 of 185